263 related articles for article (PubMed ID: 12780666)
1. The first report from the patient outcomes registry for transplant effects on life (PORTEL): differences in side-effects and quality of life by organ type, time since transplant and immunosuppressive regimens.
Hathaway D; Winsett R; Prendergast M; Subaiya I
Clin Transplant; 2003 Jun; 17(3):183-94. PubMed ID: 12780666
[TBL] [Abstract][Full Text] [Related]
2. Quality of life in kidney recipients: comparison of tacrolimus and cyclosporine-microemulsion.
Reimer J; Franke GH; Philipp T; Heemann U
Clin Transplant; 2002 Feb; 16(1):48-54. PubMed ID: 11982615
[TBL] [Abstract][Full Text] [Related]
3. A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients across Canada.
Prasad GV; Nash MM; Keough-Ryan T; Shapiro RJ
J Nephrol; 2010; 23(3):274-81. PubMed ID: 20383867
[TBL] [Abstract][Full Text] [Related]
4. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
Prasad GV; Nash MM; McFarlane PA; Zaltzman JS
Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
[TBL] [Abstract][Full Text] [Related]
5. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus.
Taylor DO; Barr ML; Radovancevic B; Renlund DG; Mentzer RM; Smart FW; Tolman DE; Frazier OH; Young JB; VanVeldhuisen P
J Heart Lung Transplant; 1999 Apr; 18(4):336-45. PubMed ID: 10226898
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressant side effect profile does not differ between organ transplant types.
Winsett RP; Stratta RJ; Alloway R; Wicks MN; Hathaway DK
Clin Transplant; 2001; 15 Suppl 6():46-50. PubMed ID: 11903386
[TBL] [Abstract][Full Text] [Related]
7. Quality of life of older patients undergoing renal transplantation: finding the right immunosuppressive treatment.
Perlman RL; Rao PS
Drugs Aging; 2014 Feb; 31(2):103-9. PubMed ID: 24399579
[TBL] [Abstract][Full Text] [Related]
8. Switching from cyclosporine to tacrolimus leads to improved disease-specific quality of life in patients after kidney transplantation.
Franke GH; Trampenau C; Reimer J;
Transplant Proc; 2006 Jun; 38(5):1293-4. PubMed ID: 16797285
[TBL] [Abstract][Full Text] [Related]
9. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation.
Armenti VT; Radomski JS; Moritz MJ; Gaughan WJ; Philips LZ; McGrory CH; Coscia LA;
Clin Transpl; 2002; ():121-30. PubMed ID: 12971441
[TBL] [Abstract][Full Text] [Related]
10. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life after different types of solid organ transplantation.
Pinson CW; Feurer ID; Payne JL; Wise PE; Shockley S; Speroff T
Ann Surg; 2000 Oct; 232(4):597-607. PubMed ID: 10998658
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
13. Neoral rescue therapy in transplant patients with intolerance to tacrolimus.
Abouljoud MS; Kumar MS; Brayman KL; Emre S; Bynon JS;
Clin Transplant; 2002 Jun; 16(3):168-72. PubMed ID: 12010138
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
15. [Quality of life following transplantation. The impact ofa new immunosuppressive substance].
Lütkes P; Franke G; Witzke O; Zimmermann U; Kohnle M; Philipp T; Heemann U
Zentralbl Chir; 1999; 124(2):90-4. PubMed ID: 10209841
[TBL] [Abstract][Full Text] [Related]
16. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
Ulsh PJ; Yang HC; Holman MJ; Ahsan N
J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
[TBL] [Abstract][Full Text] [Related]
17. Assessment of health-related quality-of-life in patients after heart transplantation under therapy with tacrolimus or cyclosporine.
von Steinbüchel N; Limm H; Leopold C; Carr D
Transpl Int; 2000; 13 Suppl 1():S609-14. PubMed ID: 11112084
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life outcomes after kidney transplantation.
Fiebiger W; Mitterbauer C; Oberbauer R
Health Qual Life Outcomes; 2004 Jan; 2():2. PubMed ID: 14713316
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
